About this episode

This episode explores how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy and its implications for future treatments.

In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Mark Lowdell , CSO & Co-Founder, INmuneBio Inc Vishwas Seshadri , CEO & Director, Abeona Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

People in this episode

Host: Jennifer C. Smith-Parker

Guests: Mark Lowdell, Vishwas Seshadri

Topics covered

• recessive dystrophic epidermolysis bullosa
• cell therapy
• gene therapy
• advanced treatments
• ultra-rare diseases

Keywords

• RDEB
• cell and gene therapy
• rare disease
• advanced treatments
• biotechnology

Mentioned in this episode

Organizations: INmuneBio Inc, Abeona Therapeutics

More episodes of BioSpace

• The future of pain relief: Exploring opioid alternatives · July 16, 2026 · 19 min
• Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup · July 15, 2026 · 21 min
• Bonus: Q2 2026 Job Market Update · July 14, 2026 · 9 min
• From sequence to scale: Gene editing’s new era in biologics manufacturing · July 10, 2026 · 21 min
• Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil · July 8, 2026 · 17 min
• Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water · July 1, 2026 · 23 min

Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.